Dec 13, 2021
Acacia Pharma Announces Successful Completion of BARHEMSYS® Post-approval Requirement Study in Patients with Severe Renal Impairment
Acacia Pharma has created a portfolio of differentiated hospital products primarily for use by anesthesia and surgical teams and a promising late-stage development candidate targeting oncologists.
Acacia Pharma commercializes its current products directly in the US via its own commercial organization targeting anesthesia and surgical teams.Partnering
Acacia Pharma is a commercial stage biopharmaceutical group focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy.Investors